Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Brexpiprazole QW Formulation in Schizophrenia
NCT04118127Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brexpiprazole orally disintegrating tablet in schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration (Cmax) of OPC-34712 Following Single Oral Administration, Time to Maximum Plasma Concentration (Tmax) of OPC-34712 Following Single Oral Administration and 2 more. Started Oct 2019; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04118127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04118127.